In Brief: SmithKline Beecham's Tagamet HB
This article was originally published in The Tan Sheet
Executive Summary
SmithKline Beecham's Tagamet HB: Single-tablet 200 mg dose is reaching wide distribution. The new form of the OTC H2 antagonist stomach medication was approved Aug. 21 and replaces the former two-per-dose 100 mg tablet. Packaging highlights the "new one-tablet dose" in a yellow flag on the box front. SB reported the approval was earlier this autumn, noting that the dual tablet dosage form had been "a major problem" in consumer perception of Tagamet HB's effectiveness and potency, causing the company to have low market share in the H2 category ("The Tan Sheet" Sept. 16, p. 1)...